Results 21 to 30 of about 1,721 (143)

Daily Vaginal Application of Dienogest (Visanne©) for 3 Months in Symptomatic Deeply Infiltrating Rectovaginal Endometriosis: A Possible New Treatment Approach?

Case Reports in Obstetrics and Gynecology, 2018
A 27-year-old patient suffering from deeply infiltrating rectovaginal endometriosis was treated with 2 mg/day dienogest vaginally for 3 months. The therapy was tolerated very well.
Andreas D. Ebert
doaj   +1 more source

Preoperative dienogest to improve the surgical field of view in resectoscopic surgery

Gynecology and Minimally Invasive Therapy, 2016
Introduction: Resectoscopic surgery requires high technological skill to perform the procedure in a limited field of vision. With the preoperative administration of dienogest, a good surgical field of vision can be secured.
Takehiko Tsuchiya, Yukiko Katagiri, Toshimitsu Maemura, Eijiro Hayata, Yusuke Fukuda, Mamoru Kitamura, Mineto Morita   +6 more
doaj   +1 more source

Postoperative management of patients with endometriosis

Акушерство, гинекология и репродукция, 2020
Aim: to assess the effectiveness of using dienogest in combination with postoperative interventions in patients with endometriosis.Materials and methods.
Ju. E. Dobrokhotova, D. M. Kalimatova, I. Yu. Ilyina   +2 more
doaj   +1 more source

Isolated Abdominal Wall Endometriosis Presenting as an Anterior Abdominal Mass: Histopathological Confirmation. [PDF]

Clin Case Rep
ABSTRACT Abdominal wall endometriosis should be considered in reproductive‐aged women presenting with painful anterior abdominal wall masses, particularly following obstetric or gynecological surgery. Histopathology confirming endometrial glands and stroma within muscle is diagnostic, even when pelvic organs are spared.
Ahsan MU, Shaheen S, Mudasir M, Qadir N, Ahmed S.   +4 more
europepmc   +2 more sources

Use of dienogest in endometriosis. A narrative literature review and expert commentary

Репродуктивная эндокринология, 2020
Objective: Endometriosis affects up to 10% of women of reproductive age, and the main goal of treatment is to relieve symptoms. Progestins have been the mainstay of endometriosis suppression, of which dienogest has become an important option in many ...
Ally Murji, Kutay Biberoğlu, Jinhua Leng   +2 more
doaj   +1 more source

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice

Reproductive Biology and Endocrinology, 2018
Background Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied.
Bo Liang, Ling Wu, Hui Xu, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu Wang   +6 more
doaj   +1 more source

Three‐dimensional patient‐derived endometriosis model for drug evaluation

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
In this study, we developed a coculturing model with stromal cells and epithelial organoids to mimic the endometriotic lesion and for further evaluation of drug effects. Abstract Introduction Endometriomsis (EMs) is a complex and chronic gynecological disease characterized by distressing symptoms.
Yuqi Li, Wei Shao, Xiaoxiao Gao, Yongxing Wang, Jinzhi Li, Liansuo Zhang, Yanyan Xing, Wentao Su, Yan Cheng, Li Wang, Songping Liu   +10 more
wiley   +1 more source

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L. Westhoff, Kristina Gemzell‐Danielsson   +9 more
wiley   +1 more source

Efficacy of 0.5 mg Dienogest Tablets in Treating Premenstrual Syndrome-like Symptoms: A Comparative Study with a Low-Dose Estrogen–Progestin Combination

Endocrines
Dysmenorrhea treatment with 0.5 mg dienogest tablets twice daily (1 mg/day) has proven useful, but its effect on premenstrual disorders has not yet been evaluated.
Haruko Yokosuka
doaj   +1 more source

Information on the combined hormonal contraceptives (CHC) containing the dienogest + ethinyl estradiol combination (Jeanine®)

Акушерство, гинекология и репродукция, 2019
In this short communication, the editorial board publishes the information on safety of the combined hormonal contraceptive (CHC) Jeanine®, containing the fixed dose combination of dienogest and ethinyl estradiol.
A. D. Makatsariya, V. O. Bitsadze, D. V. Blinov, D. I. Korabelnikov   +3 more
doaj   +1 more source